Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15440894 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1HSD11B1SLC1A2SLC1A1 | |
| SCHEMBL30950334 | 0.90 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1SLC1A2SLC1A1NPSR1 | |
| SCHEMBL11301100 | 0.87 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL3679801 | 0.87 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL676616 | 0.86 | GRM2 (0.31) | — | |
| SCHEMBL76019 | 0.80 | GRM4 (0.37) | ALDH1A1HSD11B1SLC1A2SLC1A1 | |
| SCHEMBL15440623 | 0.80 | GRM4 (0.37) | ALDH1A1HSD11B1SLC1A2SLC1A1 | |
| SCHEMBL905297 | 0.79 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL905296 | 0.79 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1GLANPSR1 | |
| SCHEMBL14216723 | 0.79 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1HSD11B1GLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007070092-A2 | METAL-CONTAINING COMPOSITIONS AND METHOD OF MAKING SAME | PRYOG, LLC (US) | 2007-06-21 | — | — | WO | claimed |
| US-20140031579-A1 | METHOD OF PRODUCING NORBORNANEDICARBOXYLIC ACID ESTER | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2014-01-30 | — | — | US | disclosed |
| CN-103459365-A | Method for producing norbornane dicarboxylic acid ester | HITACHI CHEMICAL CO LTD | 2013-12-18 | — | — | CN | disclosed |
| CN-102812063-A | Production method for polyamide having norbornane skeleton, and polyamide having norbornane skeleton obtained by means of same | HITACHI CHEMICAL CO LTD | 2012-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031579-A1 | METHOD OF PRODUCING NORBORNANEDICARBOXYLIC ACID ESTER | HSD11B2, HSD17B12, HSD11B1 | ALDH1A1 352/4885L3MBTL1 3956/4885HSD11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.